Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies the side effects and how well radiation therapy and durvalumab with or without tremelimumab work in treating participants with bladder cancer that cannot be removed by surgery, has spread to nearby tissue or lymph nodes, or that has spread to other parts of the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving radiation therapy and durvalumab with or without tremelimumab will work better in treating participants with bladder cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the safety profile of radiation therapy (RT) and durvalumab with or without tremelimumab. (Safety lead-in cohort) II. To determine the median progression-free survival with RT and durvalumab with or without tremelimumab. (Expansion cohort) SECONDARY OBJECTIVES: I. To assess the efficacy of RT and durvalumab with or without tremelimumab in terms of local control of irradiated bladder tumor. II. To assess the efficacy of RT and durvalumab with or without tremelimumab in terms of pathologic complete response (CR) rate of irradiated bladder tumor. III. To assess the efficacy of RT and durvalumab with or without tremelimumab in terms overall response rate. IV. To assess the efficacy of RT and durvalumab with or without tremelimumab in terms of abscopal response rate. V. To assess the efficacy of RT and durvalumab with or without tremelimumab in terms of duration of response. VI. To assess the efficacy of RT and durvalumab with or without tremelimumab in terms of disease specific survival. VII. To assess the efficacy of RT and durvalumab with or without tremelimumab in terms of overall survival. VIII. To further determine the safety and tolerability of RT + durvalumab with or without tremelimumab (expansion cohorts). EXPLORATORY OBJECTIVES: I. To explore the immunologic changes associated with the combination of durvalumab and RT +/- tremelimumab. OUTLINE: Participants are randomized to 1 of 2 regimens. REGIMEN A: Participants receive durvalumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo external beam radiation therapy (EBRT) for 5 fractions beginning on day 8 of course 1. REGIMEN B: Participants receive tremelimumab IV over 60 minutes on day 1 for up to 2 courses and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression of unacceptable toxicity. Participants also receive undergo EBRT for 5 fractions beginning on day 8 of course 1. After completion of study treatment, participants are followed up at 8 weeks and then every 12 and 16 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03601455
Study type Interventional
Source Jonsson Comprehensive Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 26, 2018
Completion date January 31, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03039413 - Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy Early Phase 1
Completed NCT02989064 - MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers Phase 1
Terminated NCT00072137 - Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Phase 1
Withdrawn NCT05564416 - Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Phase 2
Recruiting NCT04570410 - Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma Phase 2
Recruiting NCT06167356 - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Terminated NCT05052372 - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Terminated NCT03266900 - A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival Early Phase 1
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Active, not recruiting NCT03473730 - Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer Early Phase 1
Active, not recruiting NCT03138824 - Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC N/A
Recruiting NCT05788484 - A Study of CDX-585 in Patients With Advanced Malignancies Phase 1
Recruiting NCT05669430 - A Study of GV20-0251 in Patients With Solid Tumor Malignancies Phase 1
Active, not recruiting NCT04216290 - A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study) Phase 2
Recruiting NCT06416319 - Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct) N/A
Active, not recruiting NCT03775265 - Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Phase 3
Not yet recruiting NCT06263153 - Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Phase 2
Completed NCT00238420 - Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Phase 1/Phase 2
Active, not recruiting NCT02496208 - Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Phase 1
Recruiting NCT04985604 - Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors Phase 1/Phase 2